TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Perseus Proteomics, Inc. ( (JP:4882) ).
Perseus Proteomics Inc. reported its financial results for the fiscal year ended March 31, 2025, showing a slight increase in net sales but continued losses in operating and ordinary income. Despite the financial challenges, the company improved its cash position, ending the year with higher cash and cash equivalents. The financial results forecast for the next fiscal year is unavailable due to calculation difficulties, indicating uncertainty in future performance.
More about Perseus Proteomics, Inc.
Perseus Proteomics Inc. operates in the biotechnology industry, focusing on the development and commercialization of proteomics-based products and services. The company is listed on the Tokyo Stock Exchange and is involved in the research and development of therapeutic antibodies.
Average Trading Volume: 1,422,267
Technical Sentiment Signal: Sell
Current Market Cap: Yen6.34B
For detailed information about 4882 stock, go to TipRanks’ Stock Analysis page.